Login to Your Account

Will Kythera Biopharma's ATX 101 be the Next Botox?

By Catherine Shaffer

Wednesday, September 1, 2010
Now that Kythera Biopharmaceuticals Inc. has granted rights for ATX 101 to Intendis, a Bayer HealthCare company, in a deal potentially worth $373 million, the landscape for fat reduction drugs is expanding beyond therapeutic obesity indications and into the lucrative aesthetics market. Body shaping technologies are one of the fastest-growing sectors of that rapidly expanding market. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription